Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant Pipeline and Regulatory Milestones Achieves Positive Results from POETYK-PSO-1 Evaluating Deucravacitinib (TYK2 inhibitor) for the Treatment of Moderate to Severe Plaque […]
Other News
Cardiovascular Systems, Inc. Reports Fiscal 2021 First-Quarter Financial Results
Conference Call Scheduled for Today, November 4, 2020, at 3:30 PM CT (4:30 PM ET) Revenues of $60.5 million increased 42% sequentially and decreased 6.1% compared to last year Net loss was $2.1 million, or $0.05 per basic and diluted share Management provides fiscal 2021 second quarter revenue guidance of […]
GBT Tokenize to Add Blood Pressure Measurement Feature to qTerm Device
Version II Aim to Release Q1/2021 SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”), announced that its joint Venture GBT Tokenize Corp (“GBT/Tokenize”) is currently developing an additional feature for its qTerm device. The additional feature will be a blood […]
Cytokinetics Reports Third Quarter 2020 Financial Results
Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Primary results from GALACTIC-HF to be presented as Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2020 on November 13, 2020 Enrollment Completed in […]
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA® (icosapent ethyl) Approval and Commercialization in Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the […]
National Survey of Heart Valve Patients Reveals Missed Opportunities for Clinical Trial Awareness & Enrollment
TORRANCE, Calif., Nov. 5, 2020 /PRNewswire/ — HeartValveSurgery.com, a leading patient advocacy group for patients with heart valve disease, today released results of a new survey finding that most heart valve patients are “not very aware” of clinical trials, but most patients would consider enrolling in a clinical trial. The nationwide survey was […]
Semler Reports Record Third Quarter and Year-to-Date 2020 Financial Results
2020 Q3 HIGHLIGHTS compared to Q2 2020: – Revenues were $10,727,000, an increase of $4,354,000, or 68%, compared to $6,373,000 – Pre-tax net income of $5,595,000, an increase of $4,605,000, or 465%, compared to $990,000 – Net income was $4,866,000, or $0.74 per basic share and $0.61 per diluted share, […]
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments FREMONT, Calif., Nov. 5, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for […]
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack KING OF PRUSSIA, Pa., Nov. 5, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) has been […]
BD Announces Fiscal Fourth Quarter And Full Year 2020 Results; Provides Fiscal 2021 Guidanc
– Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis. – BD’s COVID-19 testing sales totaled more than $440 million in the fourth fiscal quarter. – Fiscal fourth quarter GAAP EPS were $0.36. Non-GAAP EPS were $2.79. FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ — […]
